FDA Requires Safety Label Update for Opioid Analgesics

Share this content:
FDA Stipulates Safety Label Update for Opioid Analgesics
FDA Stipulates Safety Label Update for Opioid Analgesics

(HealthDay News) -- In an attempt to reduce the risks of misuse, abuse, addiction, and other complications associated with extended-release and long-acting (ER/LA) opioid pain relievers, the U.S. Food and Drug Administration is requiring changes to safety labeling as well as post-market studies of the drugs.

The labeling changes are intended to better guide health care professionals in tailoring the prescription of such analgesic medications to their patient's specific needs. For instance, the labeling changes will clarify that ER/LA opioids are not indicated for use on an as-needed basis, but for patients with chronic, severe pain for whom alternatives are ineffective.

Related: Opioid Equianalgesic Doses

The FDA is also requiring further studies and clinical trials of ER/LA opioid analgesics in order to better assess the already known risks associated with their use, such as hyperalgesia, overdose, and death.

"Today's action demonstrates the FDA's resolve to reduce the serious risks of long-acting and extended-release opioids while still seeking to preserve appropriate access for those patients who rely on these medications to manage their pain," Margaret A. Hamburg, M.D., Commissioner of the FDA, said in a statement.

More Information

Related Resources

You must be a registered member of Cancer Therapy Advisor to post a comment.

Sign Up for Free e-newsletters

Regimen and Drug Listings


Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Prostate Cancer Regimens Drugs
Rare Cancers Regimens
Renal Cell Carcinoma Regimens Drugs
Skin Cancer Regimens Drugs
Urologic Cancers Regimens Drugs